Valuation: Sernova

Market Cap 41.54M 29.14M 25.89M 24.17M 22.03M 2.8B 41.93M 292M 113M 1.43B 109M 107M 4.6B P/E 2026 *
-4.2x
P/E 2027 * -3.5x
Enterprise Value 41.54M 29.14M 25.89M 24.17M 22.03M 2.8B 41.93M 292M 113M 1.43B 109M 107M 4.6B EV / Sales 2026 *
-
EV / Sales 2027 * 16.6x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 week+16.67%
1 month-8.70%
3 months-19.23%
6 months-30.00%
Current year-19.23%
1 week 0.08
Extreme 0.085
0.12
1 month 0.08
Extreme 0.085
0.15
3 years 0.08
Extreme 0.085
0.82
5 years 0.08
Extreme 0.085
2.22
10 years 0.08
Extreme 0.085
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%+22.22%-41.67%-86.36% 29.15M
+0.84%-3.74%-26.69%+1.85% 167B
-0.07%-2.55%-9.53%+11.07% 111B
+0.90%+1.13%-24.83%+0.58% 105B
-1.24%-1.31%-48.43%-13.54% 74.82B
-0.24%+0.69%+0.16%+72.58% 59.11B
-0.86%+4.49%+17.49%+57.78% 51.8B
-0.71%-3.82%-7.72%-31.41% 48.5B
+0.12%-0.17%-18.21%+20.29% 40.79B
-1.01%-1.45%+28.48%-9.72% 32.54B
Average -0.25%-0.39%-13.10%+2.31% 76.68B
Weighted average by Cap. +0.02%-0.97%-15.96%+9.93%

Financials

2026 *2027 *
Net sales - 2.5M 1.75M 1.56M 1.45M 1.33M 169M 2.52M 17.6M 6.82M 86.19M 6.58M 6.44M 277M
Net income -11.3M -7.93M -7.04M -6.57M -5.99M -762M -11.41M -79.55M -30.83M -390M -29.76M -29.12M -1.25B -13.9M -9.75M -8.66M -8.09M -7.37M -937M -14.03M -97.85M -37.92M -479M -36.61M -35.81M -1.54B
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
26-10-02 $0.1050 -4.55%
26-10-01 $0.1100 +4.76%
26-09-30 $0.1050 +16.67%
26-09-29 $0.0900 0.00%
26-09-28 $0.0900 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1050CAD
Average target price
1.000CAD
Spread / Average Target
+852.38%

Quarterly revenue - Rate of surprise